Investor's Business Daily on MSN
10x Genomics shows market leadership with jump to 92 RS rating
10x Genomics sees its Relative Strength Rating enter the elite 90-plus level.
PLEASANTON, Calif. and SINGAPORE, July 17, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, and the A*STAR Genome Institute of Singapore (A*STAR GIS) ...
Collaboration with Dana-Farber Cancer Institute aims to identify biomarkers linked to treatment response for the next generation of cancer therapies and to define a clinical reporting framework to ...
Learn more about whether Revvity, Inc. or 10x Genomics, Inc. is a better investment based on AAII's A+ Investor grades, which ...
PLEASANTON, Calif., Jan. 12, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced a collaboration with Brigham & Women's Hospital, a ...
Arc Institute continues its work to generate and share large-scale, high-quality datasets of cell state before and after chemical or genetic perturbations to enable “virtual cell” models and other ...
10x Genomics (NASDAQ:TXG) is set to give its latest quarterly earnings report on Thursday, 2026-02-12. Here's what investors need to know before the announcement. Analysts estimate that 10x Genomics ...
PLEASANTON, Calif., Aug. 7, 2025 /PRNewswire/ -- 10x Genomics, Inc. (TXG) (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it has signed a definitive agreement to ...
10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, and the A*STAR Genome Institute of Singapore (A*STAR GIS), today announced a research collaboration for the Target ...
PLEASANTON, Calif., Jan. 12, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced a collaboration with Dana-Farber Cancer Institute to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results